SI-BONE, Inc.: Form 10-Q for the period ended Sep 30, 2022
Filed with the SEC on Nov 8, 2022 and accepted by EDGAR at Nov 8, 2022, 16:07 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-07-01 to 2022-09-30 | $26.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2022-01-01 to 2022-09-30 | $74.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2022-07-01 to 2022-09-30 | $4.2m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2022-01-01 to 2022-09-30 | $10.6m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2022-07-01 to 2022-09-30 | $22.3m | us-gaap:GrossProfit |
| Gross profit | 9 months2022-01-01 to 2022-09-30 | $63.8m | us-gaap:GrossProfit |
| Research and development | 3 months2022-07-01 to 2022-09-30 | $3.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2022-01-01 to 2022-09-30 | $10.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-07-01 to 2022-09-30 | −$13.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-01-01 to 2022-09-30 | −$48.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-07-01 to 2022-09-30 | $755.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2022-01-01 to 2022-09-30 | $1.9m | us-gaap:InterestExpense |
| Income tax | 3 months2022-07-01 to 2022-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-01-01 to 2022-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-07-01 to 2022-09-30 | −$14.2m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-01-01 to 2022-09-30 | −$50.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-07-01 to 2022-09-30 | −$0.41 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-01-01 to 2022-09-30 | −$1.47 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-07-01 to 2022-09-30 | −$0.41 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-01-01 to 2022-09-30 | −$1.47 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-07-01 to 2022-09-30 | 34,356,850 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-01-01 to 2022-09-30 | 34,069,357 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-01-01 to 2022-09-30 | −$34.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2022-01-01 to 2022-09-30 | $7.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-09-30 | $26.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-09-30 | $139.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-09-30 | $158.3m | us-gaap:Assets |
| Current liabilities | At period end2022-09-30 | $18.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-09-30 | $55.4m | us-gaap:Liabilities |
| Long-term debt | At period end2022-09-30 | $33.7m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2022-09-30 | $1.5m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2022-09-30 | $102.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001459839-22-000044. Last ingested by Listed: Nov 6, 2026, 18:09 ET. Listed shows no prices and gives no investment advice.